Probing structure of neurotransmitter transporters by substituted- cysteine accessibility method

Methods in Enzymology

Volumn 296, Issue , 1998, Pages 331-346

  Javitch, Jonathan A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYSTEINE; DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROTRANSMITTER;

AMINO ACID SUBSTITUTION; BINDING SITE; CONFORMATIONAL TRANSITION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; REVIEW; SITE DIRECTED MUTAGENESIS; SYNAPTIC TRANSMISSION;

EID: 0031660683     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(98)96025-6     Document Type: Article

References (53)

1. A. P. Todd, J. Cong, F. Levinthal, C. Levinthal, and W. L. Hubbell, Proteins 6, 294 (1989).
2. K. S. Jakes, C. K. Abrams, A. Finkelstein, and S. L. Slatin, J. Biol. Chem. 265, 6984 (1990).
3. C. Altenbach, T. Marti, H. G. Khorana, and W. L. Hubbell, Science 248, 1088 (1990).
4. C. L. Careaga and J. J. Falke, Biophys. J. 62, 209 (1992).
5. A. A. Pakula and M. I. Simon, Proc. Natl. Acad. Sci. USA 89, 4144 (1992).
6. K. Jung, H. Jung, J. Wu, G. G. Prive, and H. R. Kaback, Biochemistry 32, 12273 (1993).
7. M. H. Akabas, D. A. Stauffer, M. Xu, and A. Karlin, Science 258, 307 (1992).
8. M. H. Akabas, C. Kaufmann, P. Archdeacon, and A. Karlin, Neuron 13, 919 (1994).
9. M. H. Akabas and A. Karlin, Biochemistry 34, 12496 (1995).
10. M. Xu, D. F. Covey, and M. H. Akabas, Biophys. J. 69, 1858 (1995).
11. M. Xu and M. H. Akabas, J. Biol. Chem. 268, 21505 (1993).
12. M. H. Akabas, C. Kaufmann, T. A. Cook, and P. Archdeacon, J. Biol. Chem. 269, 14865 (1994).
13. R. T. Yan and P. C. Maloney, Proc. Natl. Acad. Sci. USA 92, 5973 (1995).
14. J. M. Pascual, C. C. Shieh, G. E. Kirsch, and A. M. Brown, Biophys. J. 69, 428 (1995).
15. D. Fu, J. A. Ballesteros, H. Weinstein, J. Chen, and J. A. Javitch, Biochemistry 35, 11278 (1996).
16. J. A. Javitch, D. Fu, and J. Chen, Biochemistry 34, 16433 (1995).
17. J. A. Javitch, D. Fu, J. Chen, and A. Karlin, Neuron 14, 825 (1995).
18. J. A. Javitch, X. Li, J. Kaback, and A. Karlin, Proc. Natl. Acad. Sci. USA 91, 10355 (1994).
19. B. Giros and M. G. Caron, Trends Pharmacol. Sci. 14, 43 (1993).
20. D. A. Stauffer and A. Karlin, Biochemistry 33, 6840 (1994).
21. D. D. Roberts, S. D. Lewis, D. P. Ballou, S. T. Olson, and J. A. Shafer, Biochemistry 25, 5595 (1986).
22. R. T. Yan and P. C. Maloney, Cell 75, 37 (1993).
23. Y. Olami, A. Rimon, Y. Gerchman, A. Rothman, and E. Padan, J. Biol. Chem. 272, 1761 (1997).
24. 23 The success of this approach would depend on the number of endogenous cysteines that might also react with NEM to increase the background and on the ease and efficiency of purification.
25. J. G. Chen, S. Liu-Chen, and G. Rudnick, Biochemistry 36, 1479 (1997).
26. J. B. Wang, A. Moriwaki, and G. R. Uhl, J. Neurochem. 64, 1416 (1995).
27. M. E. Reith and G. Selmeci, Naunyn-Schmiedebergs Arch. Pharmacol. 345, 309 (1992).
28. M. M. Schweri, Neuropharmacol. 29, 901 (1990).
29. M. M. Schweri, Synapse 16, 188 (1994).
30. C. J. Cao, M. M. Young, J. B. Wong, L. G. Mahran, and M. E. Eldefrawi, Membrane Biochem. 8, 207 (1989).
31. S. M. Meiergerd and J. O. Schenk, J. Neurochem. 62, 998 (1994).
32. S. Saadouni, F. Refahi-Lyamani, J. Costentin, and J. J. Bonnet, Eur. J. Pharmacol. 268, 187 (1994).
33. K. M. Johnson, J. S. Bergmann, and A. P. Kozikowski, Eur. J. Pharmacol. 227, 411 (1992).
34. J. V. Ferrer and J. A. Javitch, Proc. Natl. Acad. Sci. USA, in press.
35. K.-K. Tai, K.-W. Wang, and S. A. N. Goldstein, J. Biol. Chem. 272, 1654 (1997).
36. M. C. Sanguinetti, M. E. Curran, A. Zou, J. Shen, P. S. Spector, D. L. Atkinson, and M. T. Keating, Nature 384, 80 (1996).
37. J. Barhanin, F. Lesage, E. Guillemare, M. Fink, M. Lazdunski, and G. Romey, Nature 384, 78 (1996).
38. These findings, however, do not rule out the possibility that some of the effects of modification are on another protein that directly interacts with the transporter and is necessary for both transport and binding.
39. 34
40. R. P. Seal and S. G. Amara, Soc. Neurosci. Abstr. 22, 1575 (1996).
41. If a water-accessible cysteine sulfhydryl is critical to the expression or function of the transporter and if reaction of such a cysteine with the MTS reagents affects binding or transport, then it may be impossible to produce the appropriate MTS-insensitive mutant. Thus, it is possible that a given protein will not be amenable to study with this method, and unfortunately this cannot be predicted in advance.
42. This approach has recently been applied to the serotonin transporter: J. G. Chen, A. Sachpatzidis, and G. Rudnick, J. Biol. Chem. 272, 28321 (1997).
43. S. Rees, J. Coote, J. Stables, S. Goodson, S. Harris, and M. G. Lee, BioTechniques 20, 1002 (1996).
44. A. Karlin and M. H. Akabas, Methods Enzymol. 293, 123 (1998).
45. J. A. Javitch, D. Fu, and J. Chen, Molec. Pharmacol. 49, 692 (1996).
46. T. E. Creighton, "Proteins: Structures and Molecular Properties," W. H. Freeman and Co., New York, 1993.
47. C. Chothia, J. Molec. Biol. 105, 1 (1976).
48. M. Levitt, Biochemistry 17, 4277 (1978).
49. P. Y. Chou and G. D. Fasman, J. Molec. Biol. 115, 135 (1977).
50. M. Holmgren, Y. Liu, Y. Xu, and G. Yellen, Neuropharmacol. 35, 797 (1996).
51. 15-18 MTSEA is slightly more reactive than is MTSET, with accessible cysteines in the dopamine D2 receptor; however, MTSEA is smaller than MTSET (and the negatively charged MTSES), and it might gain more rapid access to certain residues in the water-accessible binding-site crevice simple because of reduced steric hindrance. Moreover, MTSEA shares with dopamine the ethylamine moiety, and its increased reactivity relative to MTSET may also result from an affinity reaction with the dopamine binding site.
52. T. Schirmer, T. A. Keller, Y. F. Wang, and J. P. Rosenbusch, Science 267, 512 (1995).
53. K. A. Brown, E. E. Howell, and J. Kraut, Proc. Natl. Acad. Sci. USA 90, 11753 (1993).